Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Geier

Showing results (191-200 of 249) with videos related to

Pageof 25
Sort By:
Annals of Hepatology|August 15, 2024
Evaluation of four chatbots in autoimmune liver disease: A comparative analysisJimmy Daza, Lucas Soares Bezerra, Laura Santamaría, et al.
Journal of Clinical Medicine|April 3, 2021
Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from GermanyAnne-Christin Beatrice Wilde, Charlotte Lieb, Elise Leicht, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2023
Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based studyNajib Ben Khaled, Bernhard Mörtl, Dominik Beier, et al.
Zeitschrift Fur Gastroenterologie|March 24, 2026
Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease - Data from the German SLD-RegistryAndreas Geier, Martin A Kabelitz, Monika Rau, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2023
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based studyNajib Ben Khaled, Bernhard Mörtl, Dominik Beier, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feedingLina Jegodzinski, Lorena Rudolph, Darko Castven, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Cells|December 23, 2022
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and AmidationMarta Alonso-Peña, Ricardo Espinosa-Escudero, Heike M Hermanns, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Pageof 25

Showing results (191-200 of 249) with videos related to

Sort By:
Pageof 25
Annals of Hepatology|August 15, 2024
Evaluation of four chatbots in autoimmune liver disease: A comparative analysisJimmy Daza, Lucas Soares Bezerra, Laura Santamaría, et al.
Journal of Clinical Medicine|April 3, 2021
Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from GermanyAnne-Christin Beatrice Wilde, Charlotte Lieb, Elise Leicht, et al.
European Journal of Cancer (Oxford, England : 1990)|December 30, 2023
Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based studyNajib Ben Khaled, Bernhard Mörtl, Dominik Beier, et al.
Zeitschrift Fur Gastroenterologie|March 24, 2026
Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease - Data from the German SLD-RegistryAndreas Geier, Martin A Kabelitz, Monika Rau, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2023
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based studyNajib Ben Khaled, Bernhard Mörtl, Dominik Beier, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feedingLina Jegodzinski, Lorena Rudolph, Darko Castven, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Cells|December 23, 2022
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and AmidationMarta Alonso-Peña, Ricardo Espinosa-Escudero, Heike M Hermanns, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Pageof 25